Black Rock Inc. Checkpoint Therapeutics, Inc. Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.02 - $10.6 $6,957 - $72,302	-6,821 Reduced 0.71%	956,364 $995,000
Q2 2022 Aug 12, 2022	BUY	$0.97 - $1.77 $34,788 - $63,479	35,864 Added 3.87%	963,185 $992,000
Q1 2022 May 12, 2022	BUY	$1.53 - $3.25 $2,668 - $5,668	1,744 Added 0.19%	927,321 $1.64 Million
Q4 2021 Feb 10, 2022	SELL	$2.68 - $4.46 $25,722 - $42,807	-9,598 Reduced 1.03%	925,577 $2.88 Million
Q3 2021 Nov 09, 2021	BUY	$2.5 - $3.53 $280,787 - $396,471	112,315 Added 13.65%	935,175 $3.09 Million
Q2 2021 Aug 11, 2021	BUY	$2.36 - $3.2 $1.94 Million - $2.63 Million	822,860 New	822,860 $2.43 Million

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $351M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.